AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16332231 — intervention group
Group type: COMPARATOR
Intervention: beta‐TCP + buffer (active control)
Number of subjects: 180
Study 12215691 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous ketoprofen 30 minutes before surgical incision (Group I)
Number of subjects: 50
Study 12215691 — intervention group
Group type: COMPARATOR
Intervention: Immediate post-surgical intravenous ketoprofen (Group II)
Number of subjects: 50
Study 9776040 — intervention group
Group type: EXPERIMENTAL
Intervention: Products designed to regenerate periodontal tissues
Number of subjects: 0
Study 9776040 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative procedures
Number of subjects: 0
Study 9776040 — intervention group
Group type: EXPERIMENTAL
Intervention: Human randomized controlled clinical trials
Number of subjects: 0
Study 7665806 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 21
Study 7665806 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) measures
Number of subjects: 21
Study 7665806 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect measures
Number of subjects: 21
Study 7665806 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect measures
Number of subjects: 21
Study 2576216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg/kg vecuronium
Number of subjects: 0
Study 2576216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg vecuronium
Number of subjects: 0
Study 2576216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg/kg vecuronium
Number of subjects: 0
Study 30095728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of aspirin (100 mg)
Number of subjects: 225
Study 30095728 — intervention group
Group type: COMPARATOR
Intervention: Daytime administration of aspirin (100 mg)
Number of subjects: 225
Study 25800211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25mg)
Number of subjects: 0
Study 25800211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400mg)
Number of subjects: 0
Study 25800211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25678774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone once-a-day controlled-release (CR) tablets (20 mg)
Number of subjects: 0
Study 25678774 — intervention group
Group type: COMPARATOR
Intervention: Commercial products (10 mg bis in die [bid])
Number of subjects: 0
Study 24188685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus modified FOLFOX-6
Number of subjects: 171
Study 24188685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily plus FOLFIRI
Number of subjects: 171
Study 24188685 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks plus modified FOLFOX-6
Number of subjects: 171
Study 24188685 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg every 2 weeks plus FOLFIRI
Number of subjects: 171
Study 24188685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus modified FOLFOX-6
Number of subjects: 171
Study 24188685 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus modified FOLFOX-6
Number of subjects: 171
Study 24188685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus FOLFIRI
Number of subjects: 171
Study 24188685 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 171
Study 21615341 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal bupivacaine 10 mg (Group 1)
Number of subjects: 64
Study 21615341 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 10 mg (Group 2)
Number of subjects: 64
Study 21615341 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 10 mg with sufentanil 2.5 mcg (Group 3)
Number of subjects: 64
Study 21615341 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 10 mg with sufentanil 5 mcg (Group 4)
Number of subjects: 64
Study 21615341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (Groups 3 and 4)
Number of subjects: 64
Study 19389007 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP with general anaesthesia (R1)
Number of subjects: 80
Study 19389007 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP with general anaesthesia (P1)
Number of subjects: 80
Study 19389007 — intervention group
Group type: EXPERIMENTAL
Intervention: RRP with general plus epidural anaesthesia (R2)
Number of subjects: 80
Study 19389007 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP (P1) and RRP (P2)
Number of subjects: 80
Study 19389007 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 17007707 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 200
Study 17007707 — intervention group
Group type: COMPARATOR
Intervention: Anti-smoking advice
Number of subjects: 200
Study 15289387 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 249
Study 15289387 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 249
Study 11426071 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/nevirapine
Number of subjects: 59
Study 11426071 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine/didanosine/nevirapine)
Number of subjects: 59
Study 11426071 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/didanosine
Number of subjects: 59
Study 11426071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 59
Study 8989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms/kg i.v. (Group II)
Number of subjects: 126
Study 8989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 micrograms/kg epidurally (Group III)
Number of subjects: 126
Study 8989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms/kg epidurally (Group IV)
Number of subjects: 126
Study 8989008 — intervention group
Group type: COMPARATOR
Intervention: Control (Group I: i.v. and epidural saline)
Number of subjects: 126
Study 8989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure responses
Number of subjects: 126
Study 8989008 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate responses
Number of subjects: 126
Study 7969216 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid levodopa/carbidopa (LD/CD)
Number of subjects: 5
Study 7969216 — intervention group
Group type: COMPARATOR
Intervention: Tablet levodopa/carbidopa (LD/CD)
Number of subjects: 5
Study 3620048 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose (0.5 ml) intramuscular injection of PVRV on days 0, 3, 7, 14 and 28
Number of subjects: 58
Study 3620048 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58
Study 3620048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58
Study 3620048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-site intradermal injections of PVRV (0.1 ml) on days 0, 3, and 7, followed by another intradermal injection on day 28
Number of subjects: 58
Study 29203380 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection (PI)
Number of subjects: 129
Study 29203380 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 129
Study 27411763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy-based program for reducing internalized stigma, provided for 8 weeks (12 sessions)
Number of subjects: 64
Study 27411763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study 24231135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity ergometer aerobic training (3 times per week for 6 weeks)
Number of subjects: 54
Study 24231135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic training)
Number of subjects: 54
Study 22228560 — intervention group
Group type: EXPERIMENTAL
Intervention: SterolQ₁₀ (100 mg single dose)
Number of subjects: 36
Study 22228560 — intervention group
Group type: COMPARATOR
Intervention: generic CoQ₁₀ (100 mg single dose)
Number of subjects: 36
Study 22228560 — intervention group
Group type: EXPERIMENTAL
Intervention: SterolQ₁₀ (100 mg/day for 4 weeks)
Number of subjects: 36
Study 22228560 — intervention group
Group type: COMPARATOR
Intervention: generic CoQ₁₀ (100 mg/day for 4 weeks)
Number of subjects: 36
Study 20238367 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 250
Study 20238367 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal approach to lift the sinus lining with 8 mm implants
Number of subjects: 250
Study 20238367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm short implants
Number of subjects: 250
Study 20238367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus lift procedures without bone graft
Number of subjects: 250
Study 20238367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone substitutes
Number of subjects: 250
Study 19040172 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeMasters Supported SelfCare demonstration program (disease management services)
Number of subjects: 33000
Study 16162050 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo expectation with goal activation techniques
Number of subjects: 0
Study 16162050 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo expectation with negative motivation
Number of subjects: 0
Study 16162050 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo effect measures
Number of subjects: 0
Study 14700097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Chamber Maintainer (ACM) system
Number of subjects: 132
Study 14700097 — intervention group
Group type: COMPARATOR
Intervention: No anterior chamber maintainer
Number of subjects: 132
Study 10320178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream (EMLA) applied transdermally for 3 hours before CT removal
Number of subjects: 0
Study 10320178 — intervention group
Group type: COMPARATOR
Intervention: IV morphine administered 0.5 hours before CT removal
Number of subjects: 0
Study 8943644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 40
Study 8943644 — intervention group
Group type: COMPARATOR
Intervention: Sutured closure
Number of subjects: 40
Study 1767644 — intervention group
Group type: EXPERIMENTAL
Intervention: Full weight bearing allowed after 2-4 days
Number of subjects: 61
Study 1767644 — intervention group
Group type: COMPARATOR
Intervention: Control group allowed weight bearing at 4 weeks
Number of subjects: 61
Study 6127885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32
Study 6127885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32
Study 6127885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (5 micrograms/kg/min for 30 min)
Number of subjects: 32
Study 6127885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol infusion
Number of subjects: 32
Study 30266892 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU + BEV
Number of subjects: 296
Study 30266892 — intervention group
Group type: COMPARATOR
Intervention: CCNU + placebo
Number of subjects: 296
Study 30701113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide irrigation
Number of subjects: 117
Study 30701113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrogen peroxide irrigation)
Number of subjects: 117
Study 27993193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberries (150 g, 3 times a week for 6 weeks)
Number of subjects: 36
Study 27993193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberries (150 g, 3 times a week for 6 weeks) in men
Number of subjects: 36
Study 24797228 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated polyglactin 910 antimicrobial sutures
Number of subjects: 198
Study 24797228 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure
Number of subjects: 198
Study 21557368 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral gadolinium diethylenetriaminepentaacetic acid bis‐methylamide (0.1 mmol/kg)
Number of subjects: 63
Study 21557368 — intervention group
Group type: COMPARATOR
Intervention: Ionic gadolinium diethylenetriaminepentaacetic acid (0.1 mmol/kg)
Number of subjects: 63
Study 21557368 — intervention group
Group type: COMPARATOR
Intervention: Comparison of normalized Cho between groups A and B
Number of subjects: 63
Study 19241200 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wheelchair with ESP steering conversion kit
Number of subjects: 13
Study 19241200 — intervention group
Group type: COMPARATOR
Intervention: Standard dual handrim Sunrise Breezy wheelchair
Number of subjects: 13
Study 17601896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus azithromycin (1 g per week for 2 weeks)
Number of subjects: 106
Study 17601896 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus doxycycline (200 mg/d for 2 weeks)
Number of subjects: 106
Study 15466978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette reduction (75% reduction over 6 weeks)
Number of subjects: 0
Study 15466978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hydroxypyrene
Number of subjects: 0
Study 11133600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (4 microg/kg)
Number of subjects: 134
Study 11133600 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 134
Study 9754085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU) and 70% glycolic acid (GA)
Number of subjects: 18
Study 9754085 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid (GA) alone
Number of subjects: 18
Study 8151586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucillamine (100 mg/day)
Number of subjects: 24
Study 8151586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive)
Number of subjects: 24
Study 3047337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (exact regimen not specified)
Number of subjects: 259
Study 1747791 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU) administered as a protracted venous infusion
Number of subjects: 522
Study 1036806 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 143
Study 30167975 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple exercise therapy (training and stretching the knee and hip muscles)
Number of subjects: 100
Study 30167975 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (training the quadriceps muscles)
Number of subjects: 100
Study 27438460 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression alleviation
Number of subjects: 1028
Study 25582141 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 0
Study 25582141 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 0
Study 24335178 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC+LRH (4 cycles of cisplatin, paclitaxel, and carboplatin)
Number of subjects: 21
Study 24335178 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC+LRH
Number of subjects: 21
Study 24335178 — intervention group
Group type: COMPARATOR
Intervention: LRH
Number of subjects: 21
Study 24335178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (part of NAC)
Number of subjects: 21
Study 22162990 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term stress management training
Number of subjects: 74
Study 22162990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 19656254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 40
Study 19656254 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 40
Study 17824884 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dry mouth products containing olive oil, betaine, and xylitol
Number of subjects: 40
Study 17824884 — intervention group
Group type: COMPARATOR
Intervention: Normal dry mouth routine care
Number of subjects: 40
Study 15922429 — intervention group
Group type: EXPERIMENTAL
Intervention: SWL plus PDI therapy (median of four sessions, range 1 to 12)
Number of subjects: 108
Study 15922429 — intervention group
Group type: COMPARATOR
Intervention: SWL only
Number of subjects: 108
Study 11159235 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulb test
Number of subjects: 48
Study 11159235 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe test
Number of subjects: 48
Study 11159235 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCO(2) monitoring
Number of subjects: 48
Study 11159235 — intervention group
Group type: COMPARATOR
Intervention: Bulb test and Syringe test
Number of subjects: 48
Study 9040453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg/d) with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Number of subjects: 244
Study 9040453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 244
Study 9040453 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothing techniques (moving or fixed 2-hour averages or Fourier modeling)
Number of subjects: 244
Study 7943517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic concentric training
Number of subjects: 30
Study 7943517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training
Number of subjects: 30
Study 7943517 — intervention group
Group type: COMPARATOR
Intervention: Control group with no training
Number of subjects: 30
Study 3227054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose haloperidol (0.40 mg/kg)
Number of subjects: 0
Study 3227054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose haloperidol (0.15 mg/kg)
Number of subjects: 0
Study 3227054 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dose haloperidol (0.05 mg/kg)
Number of subjects: 0
Study 29455556 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted ultrasound guidance
Number of subjects: 71
Study 29455556 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound guidance
Number of subjects: 71
Study 28898532 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV plus HM
Number of subjects: 70
Study 28898532 — intervention group
Group type: COMPARATOR
Intervention: PPV alone
Number of subjects: 70
Study 25983115 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm arthroscopic irrigation fluid (Group W)
Number of subjects: 66
Study 25983115 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation fluid (Group RT)
Number of subjects: 66
Study 23403428 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)
Number of subjects: 0
Study 23403428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22006023 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg once daily
Number of subjects: 1059
Study 22006023 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg once daily
Number of subjects: 1059
Study 22006023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 19199510 — intervention group
Group type: COMPARATOR
Intervention: 780-nm laser phototherapy
Number of subjects: 0
Study 19199510 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser phototherapy
Number of subjects: 0
Study 19199510 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation in cell cultures
Number of subjects: 0
Study 16198072 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) and Norethisterone acetate (1 mg) daily for 6 months
Number of subjects: 31
Study 16198072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15458803 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 48
Study 15458803 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus (listening to a recorded story)
Number of subjects: 48
Study 15458803 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no environmental stimuli)
Number of subjects: 48
Study 10800757 — intervention group
Group type: EXPERIMENTAL
Intervention: pure human FSH: 75 IU i.m. every other day for 3 months
Number of subjects: 183
Study 10800757 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 183
Study 8607890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (RA group)
Number of subjects: 8
Study 8607890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (young exercise group)
Number of subjects: 8
Study 8607890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (elderly exercise group)
Number of subjects: 8
Study 2005294 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treatment
Number of subjects: 0
Study 2005294 — intervention group
Group type: COMPARATOR
Intervention: Out-patient clinic treatment
Number of subjects: 0
Study 6097137 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.4 mg/kg
Number of subjects: 30
Study 6097137 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 30
Study 6097137 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1.0 mg/kg
Number of subjects: 30
Study 29787859 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (prebiotic: fructooligosaccharides 4 g/day; probiotic: Bifidobacterium animalis subsp. lactis BB-12 at a minimum of 10 billion CFU/day)
Number of subjects: 104
Study 29787859 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 104
Study 29787859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 27009579 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (SBP) in participants aged 70 years
Number of subjects: 1973
Study 27009579 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled blood pressure in participants aged 70 years
Number of subjects: 1973